AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02295280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: IV
Study NCT02295280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: iv
Study NCT02295280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: PO
Study NCT02184507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement pre CABG
Description: One sachet of the supplement was consumed daily for 7 days before surgery.
Study NCT02184507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement post CABG
Description: One sachet of the supplement was consumed daily for 30 days after surgery
Study NCT02184507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement pre and post CABG
Description: One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
Study NCT02184507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
Study NCT03092089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity, (Lipid Microspheres) Intravenous Suspension
Description: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
Study NCT03092089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myocardial Contrast Echocardiography
Description: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
Study NCT03092089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repurfusion therapy with PPCI
Description: Patients will receive reperfusion therapy with PPCI as standard of care
Study NCT01626131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Participants will engage in 3 aerobic and resistance exercise sessions (\~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form.
Study NCT01626131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching training
Description: Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (\~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
Study NCT03171610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil group
Description: PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
Study NCT03171610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl group
Description: PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
Study NCT00769678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of the diaphragm
Description: Stimulation of the diaphragm using an electrode
Study NCT01155284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Lansoprazole
Description: Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~* Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~* Subjects age 18-45 years at Visit 2 will take 2 capsules once daily
Study NCT01155284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
Study NCT03438331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Description: The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
Study NCT03438331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy for Depression (CBT-D)
Description: The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
Study NCT03863652 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention via snuffbox approach
Description: After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
Study NCT02643966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole breast ultrasound
Description: Breast cancer screening with whole breast ultrasound
Study NCT01794156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Study NCT01794156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction
Study NCT01794156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inference-based therapy
Study NCT02962531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 caplets 1600 mg (4 x 400 mg), fasted
Description: oral dose under fasted conditions
Study NCT02962531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 caplets 1600 mg (4 x 400 mg), fed
Description: oral dose under fed conditions
Study NCT02962531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 aqueous dispersion 1600 mg (20 mL), fasted
Description: oral dose under fasted conditions
Study NCT01246973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
Study NCT01246973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
Study NCT01355523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (N-acetyl-5-methoxytryptamine)
Description: 6 mg oral melatonin daily 1 hour before bedtime
Study NCT01355523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 mg oral placebo daily 1 hour before bedtime
Study NCT05437484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led BASICS
Description: The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol.
Study NCT02740673 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Driving simulator
Description: Patients are asked to use a driving simulator to test their driving skills
Study NCT02169531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ex vivo Activated Immune Cells
Description: The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
Study NCT02407028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (1.5 ATA, no NBH)
Description: HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
Study NCT02407028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.0 ATA, no NBH)
Description: HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
Study NCT02407028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.5 ATA, no NBH)
Description: HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
Study NCT02407028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (1.5 ATA + NBH)
Description: HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
Study NCT02407028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.0 ATA + NBH)
Description: HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
Study NCT02407028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.5 ATA + NBH)
Description: HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
Study NCT02407028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia (NBH)
Description: 100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
Study NCT04519229 — intervention group
Intervention type: BEHAVIORAL
Intervention: Child-Parent Psychotherapy
Description: Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
Study NCT04543929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: partially supervised and home-based exercise activity
Study NCT03473886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: PP-MI
Description: The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
Study NCT02407028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Will be treated with usual and customary care for severe traumatic brain injury
Study NCT01667965 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
Study NCT00363129 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given orally
Study NCT00363129 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01589029 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CANAKINUMAB (ILARIS®)
Description: subcutaneous injection every 8 weeks
Study NCT01252836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWBAT-D
Description: Application of AWBAT-D bioengineered device
Study NCT01252836 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AWBAT-D
Description: Application of AWBAT-D bioengineered device
Study NCT02868905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Study NCT03818919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Traditionally used narcotic pain protocol
Study NCT01886170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase II of the Study: Information regarding Current Diabetes Control
Description: Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
Study NCT03456726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be provided as a 200 mg oral tablet.
Study NCT03952936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vestibular Rehabilitation
Description: standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
Study NCT03963999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Elastography
Description: Ultrasound shear wave elastography
Study NCT03963999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Ultrasound (CEUS)
Description: Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
Study NCT03501199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet-rich fibrin placement
Description: filling the buccal gap with platelet-rich fibrin after immediate dental implant placement
Study NCT03501199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xenogenic graft placement
Description: filling the buccal gap with xenogenic graft after immediate dental implant placement
Study NCT03501199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no extra material
Description: filling the buccal gap with no material after immediate dental implant placement
Study NCT03501199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth extraction
Description: extraction of tooth which is unrestorable
Study NCT03501199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: putting dental implant into a socket which has been prepared with compatible drills
Study NCT03501199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collagen membran placement
Description: placing collagen membran on extraction socket after dental implant placement to cover all
Study NCT03501199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: raising flap
Description: raising the buccal flap with two vertical incision to cover extraction socket for primary closure
Study NCT02124642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid, 400 mcg/day
Description: The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
Study NCT02124642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 800 mcg/day
Description: The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
Study NCT03874676 — intervention group
Intervention type: OTHER
Intervention: PEACE Rounds
Description: PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
Study NCT00817089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo pill
Study NCT00817089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo pill
Study NCT00817089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg of naltrexone prior to challenge session
Study NCT03073889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp Nerve Block
Description: A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
Study NCT03073889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalp infiltration
Description: Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
Study NCT03073889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT03073889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT01663493 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNB
Study NCT00561223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost Inhalation
Description: inhale 2.5 mg, repeat times one
Study NCT00561223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: inhaled 2.5 mg, repeat times one
Study NCT03535818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
Study NCT02176317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10\^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
Study NCT03741309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% fluorocalcium phosphosilicate dentifrice
Description: dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.